For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 2,135 | |||
| General and administrative | 3,437 | |||
| Total operating expenses | 5,572 | |||
| Loss from operations | -5,572 | |||
| Interest income | 125 | |||
| Total other income (expenses) | 125 | |||
| Net loss | -5,447 | |||
| Basic EPS | -0.3 | |||
| Diluted EPS | -0.3 | |||
| Basic Average Shares | 18,427,787 | |||
| Diluted Average Shares | 18,427,787 | |||
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)